Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401
An Extension Study to Evaluate the Long-Term Safety, Tolerability, and Clinical Activity of IMO-8400 in Patients With Relapsed or Refractory Waldenström's Macroglobulinemia Who Completed Study 8400-401
Sponsor: Idera Pharmaceuticals, Inc.
This PHASE1/PHASE2 trial investigates Waldenstrom's Macroglobulinemia and is currently completed. Idera Pharmaceuticals, Inc. leads this study, which shows 7 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Dec 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Dec 2017 [monthly]
Completed PHASE1_PHASE2
Status: Enrolling By Invitation → Completed
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE1_PHASE2
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Idera Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.